Largest Prostate SBRT Studies to Date Show Accuray CyberKnife® System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
The CyberKnife System delivers radiation with sub-millimeter precision, enhancing clinicians' ability to treat effectively while preserving healthy tissue. In addition to clinical benefits, SBRT is more convenient for patients and has been shown to be less costly than long courses of intensity-modulated radiation therapy (IMRT).
Growing clinical evidence suggests that dose-escalation may translate to improved clinical outcomes for prostate cancer. Research suggests that, unlike most tumors, prostate cancer cells are highly sensitive to the amount of radiation dose delivered per fraction or treatment session. In recent years, this has led clinicians to consider hypo-fractionated schedules—the delivery of a higher dose per fraction in fewer fractions than conventional schedules—with promising results. SBRT, which combines a high degree of targeting accuracy with very high doses of extremely precise, externally-delivered radiation over four to five sessions, provides an option for accomplishing this goal.
Highlights of the Multi-Center Studies
Pinpoint precision results in exceptional survival rates
Prostate SBRT administered by the system resulted in the following disease-free survival rates:
- 97% - 100% for low-risk patients
- Superior to the 92% - 94% from conventional radiation therapy historic data
- Equivalent to low dose rate (LDR) brachytherapy and high dose rate (HDR) brachytherapy without the inconvenience and risk associated with invasive seed and catheter implants
- 88% - 97% for intermediate-risk patients
- Equal to or higher than the 85% - 90% reported with conventional radiation therapy without the inconvenience of daily visits over several weeks
Minimal toxicity even with high radiation dose
Despite the high dose delivered to the prostate, side effects were uncommon (less than two percent grade 3 or higher toxicities) and were similar to other radiation therapy procedures without the need for invasive rectal balloons or spacers to spare the rectal wall.
"Our study treated over 300 prostate cancer patients across 21 centers throughout
"These multi-center studies reinforce the value the CyberKnife System can bring to a hospital's prostate cancer treatment program and its potential to change the way the disease is treated by many physicians," said Fabienne Hirigoyenberry-Lanson, PhD, Vice President Global Medical and Scientific Affairs, at
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director, Accuray
+1 (408) 789-4426
+1 (781) 684-6662
View original content to download multimedia:http://www.prnewswire.com/news-releases/largest-prostate-sbrt-studies-to-date-show-accuray-cyberknife-system-provides-excellent-prostate-cancer-survival-rates-in-five-or-fewer-sessions-300718075.html